Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 13/20 | 0.40 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883435 | 1.00 | MAP4K4 (0.40) | MAP4K4PIM2PIM1PIM3PDE10A | |
| SCHEMBL2836000 | 1.00 | MAP4K4 (0.40) | MAP4K4PIM2PIM1PIM3PDE10A | |
| SCHEMBL18430014 | 1.00 | MAP4K4 (0.40) | MAP4K4PIM2PIM1PIM3PDE10A | |
| SCHEMBL30628530 | 1.00 | MAP4K4 (0.40) | MAP4K4PIM2PIM1PIM3PDE10A | |
| SCHEMBL13457022 | 0.91 | MAP4K4 (0.44) | MAP4K4PDE10AEIF2AK4AURKAPDPK1 | |
| SCHEMBL15109521 | 0.91 | MAP4K4 (0.44) | MAP4K4PDE10AEIF2AK4AURKAPDPK1 | |
| SCHEMBL4119084 | 0.90 | MAP4K4 (0.41) | MAP4K4PDE10AEIF2AK4AURKAPDPK1 | |
| SCHEMBL4132744 | 0.90 | MAP4K4 (0.41) | MAP4K4PDE10AEIF2AK4AURKAPDPK1 | |
| SCHEMBL2836325 | 0.87 | EIF2AK4 (0.48) | MAP4K4PIM2PIM1PIM3PDE10A | |
| SCHEMBL11912148 | 0.87 | EIF2AK4 (0.48) | MAP4K4PIM2PIM1PIM3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MAP4K4 50/4885PIM2 2/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.